Advances in DNA Vaccines
DNA is a rapidly developing vaccine platform for cancer and infectious and non-infectious diseases. Plasmids are used as immunogens to encode proteins to be further synthesized in vaccine recipients. DNA is mainly synthetic, ensuring enhanced expression in the cells of vaccine recipients (mostly mam...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2021 |
Language: | English |
Physical Description: | 1 electronic resource (210 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545570204498 |
---|---|
ctrlnum |
(CKB)5400000000042345 (oapen)https://directory.doabooks.org/handle/20.500.12854/76819 (EXLCZ)995400000000042345 |
collection |
bib_alma |
record_format |
marc |
spelling |
Isaguliants, Maria edt Advances in DNA Vaccines Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 1 electronic resource (210 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Open access Unrestricted online access star DNA is a rapidly developing vaccine platform for cancer and infectious and non-infectious diseases. Plasmids are used as immunogens to encode proteins to be further synthesized in vaccine recipients. DNA is mainly synthetic, ensuring enhanced expression in the cells of vaccine recipients (mostly mammalians). Their introduction into the host induces antibody and cellular responses. The latter are often more pronounced, and mimic the events occurring in infection, especially viral. There are a few distinct ways in which the vaccine antigen can be processed and presented, which determine the resulting immune response and which can be manipulated. Routinely, the antigen synthesized within the host cell is processed by proteasome, loaded onto, and presented in a complex with MHC I molecules. Processing can be re-routed to the lysosome, or immunogen can be secreted for further presentation in a complex with MHC II. Apart from expression, vaccination efficacy depends on DNA delivery. DNA immunogens are generally administered by intramuscular or intradermal injections, usually followed by electroporation, which enhances delivery 1000-fold. Other techniques are also used, such as noninvasive introduction by biojectors, skin applications with plasters and microneedles/chips, sonication, magnetofection, and even tattooing. An intense debate regarding the pros and cons of different routes of delivery is ongoing. A number of studies have compared the effect of delivery methods at the level of immunogen expression, and the magnitude and specificity of the resulting immune response. According to some, the delivery route determines immunogenic performance; according to others, it can modulate the level of response, but not its specificity or polarity. The progress of research aiming at the optimization of DNA vaccine design, delivery, and immunogenic performance has led to a marked increase in their efficacy in large species and humans. New DNA vaccines for use in the treatment of infectious diseases, cancer, allergies, and autoimmunity are forthcoming. This Special Issue covers various aspects of DNA vaccine development. English Medicine bicssc Epidemiology & medical statistics bicssc alphaviruses layered RNA/DNA vectors DNA vaccines RNA replicons recombinant particles tumor regression protection against tumor challenges and infectious agents ebola virus disease artificial T-cell antigens DNA vaccine constructs computer design gene expression immunogenicity DNA vaccine mRNA vaccine plasmid DNA in vitro transcribed mRNA immune responses formulations Cytolytic T Lymphocytes antibodies innate immunity adjuvants vaccine delivery plasmid cytolytic perforin bicistronic HCV HIV IL-36 adjuvant DNA Zika Epstein-Barr virus latent proteins LMP2 EBNA1 LMP1 HIV-1 enhancer element circovirus influenza immunization intranasal lipid flagellin BCG vaccine rBCG HTI T-cell AIDS clinical trial therapeutic vaccine hepatitis C virus (HCV) mesenchymal stem cells (MSC) modified MSC DNA immunization nonstructural HCV proteins immune response HCV vaccine myeloid derived suppressor cells (MDSCs) 3-0365-0300-5 3-0365-0301-3 Ljungberg, Karl edt Isaguliants, Maria oth Ljungberg, Karl oth |
language |
English |
format |
eBook |
author2 |
Ljungberg, Karl Isaguliants, Maria Ljungberg, Karl |
author_facet |
Ljungberg, Karl Isaguliants, Maria Ljungberg, Karl |
author2_variant |
m i mi k l kl |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Advances in DNA Vaccines |
spellingShingle |
Advances in DNA Vaccines |
title_full |
Advances in DNA Vaccines |
title_fullStr |
Advances in DNA Vaccines |
title_full_unstemmed |
Advances in DNA Vaccines |
title_auth |
Advances in DNA Vaccines |
title_new |
Advances in DNA Vaccines |
title_sort |
advances in dna vaccines |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2021 |
physical |
1 electronic resource (210 p.) |
isbn |
3-0365-0300-5 3-0365-0301-3 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT isaguliantsmaria advancesindnavaccines AT ljungbergkarl advancesindnavaccines |
status_str |
n |
ids_txt_mv |
(CKB)5400000000042345 (oapen)https://directory.doabooks.org/handle/20.500.12854/76819 (EXLCZ)995400000000042345 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Advances in DNA Vaccines |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1787548867242229761 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05125nam-a2201093z--4500</leader><controlfield tag="001">993545570204498</controlfield><controlfield tag="005">20231214133355.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202201s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000042345</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/76819</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000042345</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Isaguliants, Maria</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Advances in DNA Vaccines</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (210 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="a">Open access</subfield><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">DNA is a rapidly developing vaccine platform for cancer and infectious and non-infectious diseases. Plasmids are used as immunogens to encode proteins to be further synthesized in vaccine recipients. DNA is mainly synthetic, ensuring enhanced expression in the cells of vaccine recipients (mostly mammalians). Their introduction into the host induces antibody and cellular responses. The latter are often more pronounced, and mimic the events occurring in infection, especially viral. There are a few distinct ways in which the vaccine antigen can be processed and presented, which determine the resulting immune response and which can be manipulated. Routinely, the antigen synthesized within the host cell is processed by proteasome, loaded onto, and presented in a complex with MHC I molecules. Processing can be re-routed to the lysosome, or immunogen can be secreted for further presentation in a complex with MHC II. Apart from expression, vaccination efficacy depends on DNA delivery. DNA immunogens are generally administered by intramuscular or intradermal injections, usually followed by electroporation, which enhances delivery 1000-fold. Other techniques are also used, such as noninvasive introduction by biojectors, skin applications with plasters and microneedles/chips, sonication, magnetofection, and even tattooing. An intense debate regarding the pros and cons of different routes of delivery is ongoing. A number of studies have compared the effect of delivery methods at the level of immunogen expression, and the magnitude and specificity of the resulting immune response. According to some, the delivery route determines immunogenic performance; according to others, it can modulate the level of response, but not its specificity or polarity. The progress of research aiming at the optimization of DNA vaccine design, delivery, and immunogenic performance has led to a marked increase in their efficacy in large species and humans. New DNA vaccines for use in the treatment of infectious diseases, cancer, allergies, and autoimmunity are forthcoming. This Special Issue covers various aspects of DNA vaccine development.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidemiology & medical statistics</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">alphaviruses</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">layered RNA/DNA vectors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA vaccines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RNA replicons</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">recombinant particles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor regression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">protection against tumor challenges and infectious agents</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ebola virus disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">artificial T-cell antigens</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA vaccine constructs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">computer design</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunogenicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mRNA vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">plasmid DNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vitro transcribed mRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune responses</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">formulations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cytolytic T Lymphocytes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">innate immunity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adjuvants</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccine delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">plasmid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytolytic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">perforin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bicistronic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HCV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HIV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IL-36</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adjuvant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Zika</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Epstein-Barr virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">latent proteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">LMP2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EBNA1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">LMP1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HIV-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">enhancer element</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">circovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">influenza</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intranasal</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lipid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">flagellin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BCG</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rBCG</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HTI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T-cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AIDS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hepatitis C virus (HCV)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mesenchymal stem cells (MSC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">modified MSC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA immunization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nonstructural HCV proteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HCV vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">myeloid derived suppressor cells (MDSCs)</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-0300-5</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-0301-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ljungberg, Karl</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Isaguliants, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ljungberg, Karl</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:52:05 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337983580004498&Force_direct=true</subfield><subfield code="Z">5337983580004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337983580004498</subfield></datafield></record></collection> |